Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, a public interest team of attorneys and scientists who ensure that patents do not obstruct access to affordable medicines for patients in the United States and around the world, discusses transparency in drug pricing.
Transcript:
Drug makers often argue that developing a drug is so costly that high prices are warranted to recoup their costs and reward innovation. What do you think about that argument?
I think that’s a fair argument, and we know that there are a lot of costs that go into drug development and research. What those exact costs are we don’t exactly know, it’s a bit of a black box, and I think some transparency around that would be helpful so that these debates and these discussions can be more informed. But we don’t believe that all the various patents that are being filed warrant or explain all the costs and the sort of profits that are being made as a result of these strategies that companies are using in order to prevent competition.
I think those are separate issues, and they need to be unpackaged better to have a better policy to help both the payers and the public in order to get fairer pricing; but also to actually better improve what kind of [research and development, R&D] is done, what kind of innovation comes out of the system because at the moment I feel the patent system is an incentive mechanism which is not functioning at its highest possible way.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.